Estrace

Atrophic Vaginitis, Low Testosterone, Hypogonadism + 27 more
Treatment
5 FDA approvals
20 Active Studies for Estrace

What is Estrace

EstradiolThe Generic name of this drug
Treatment SummaryEstradiol is a hormone naturally produced in female bodies. It is used in hormone therapy to treat conditions caused by reduced estrogen such as vaginal dryness and hot flashes. It can be taken orally in the form of tablets, injections, or rings, or applied directly on the skin in the form of patches, sprays, gels, or creams. A synthetic form of estradiol called ethinyl estradiol is used in combination with other hormones in oral contraceptives as it is more resistant to metabolism and has a higher bioavailability.
Estradermis the brand name
image of different drug pills on a surface
Estrace Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Estraderm
Estradiol
1986
373

Approved as Treatment by the FDA

Estradiol, also known as Estraderm, is approved by the FDA for 5 uses like Hormonal Contraception and Breast Cancer .
Hormonal Contraception
Used to treat Hormonal Contraception therapy in combination with Levonorgestrel
Breast Cancer
Birth Control
Used to treat Contraception in combination with Levonorgestrel
Palliative Treatment
Breast Cancer

Effectiveness

How Estrace Affects PatientsEstradiol is a medication used to relieve hot flashes and other menopausal symptoms such as vaginal dryness and discomfort during intercourse. It also helps increase bone density, improve the lipid profile of the blood, and increase the levels of certain proteins in the liver. Additionally, it can reduce the formation of follicle-stimulating hormone in the brain. However, estradiol should not be used by people at risk of cardiovascular diseases, blood clots, or stroke, as it can cause an increase in coagulation in the blood. It can also cause an increase in sodium retention and blood pressure.
How Estrace works in the bodyEstrogen is found in many different parts of the body, and it plays a big role in women's reproductive health. During a woman's reproductive years, most of the estrogen in her body comes from the ovarian follicle. After menopause, however, most estrogen is produced from a hormone called androstenedione that's secreted by the adrenal cortex. Estradiol is more powerful than other forms of estrogen, but postmenopausal women have higher levels of estrone which can cause symptoms like hot flashes, chills, mood swings, and sleep problems. Estradiol works by

When to interrupt dosage

The advised dosage of Estrace is contingent upon the specified ailment, including Premature Menopause, Pharmaceutical Preparations and Postmenopause. The quantity of dosage fluctuates, commensurate with the method of administration featured in the table below.
Condition
Dosage
Administration
Osteoporosis
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Vasomotor System
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Hormonal Contraception
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Balanitis Xerotica Obliterans
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
female castration
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
estradiol
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Breast
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Pharmaceutical Preparations
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Hypogonadism
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
hypoestrogenism
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Hot flashes
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Hormone Replacement Therapy
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Postmenopause
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Breast Cancer
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Palliative Treatment
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Osteoporosis, Postmenopausal
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Hot Flashes
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Premature Menopause
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Atrophic
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal
Prostate Cancer
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
, Topical, Gel, metered, Gel, metered - Topical, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Vaginal, Ring, Ring - Vaginal, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert, Insert - Vaginal, Cream, Cream - Vaginal, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Warnings

Estrace Contraindications
Condition
Risk Level
Notes
Breast
Do Not Combine
Angioedema
Do Not Combine
Venous Thrombosis
Do Not Combine
undiagnosed abnormal genital bleeding
Do Not Combine
estrogen-dependent neoplasia
Do Not Combine
Liver Dysfunction
Do Not Combine
Breast
Do Not Combine
suspected pregnancy
Do Not Combine
Breast Cancer
Do Not Combine
Pulmonary Embolism
Do Not Combine
Angioedema
Do Not Combine
Deep Vein Thrombosis
Do Not Combine
Thromboembolism
Do Not Combine
Neoplasms, Hormone-Dependent
Do Not Combine
Pulmonary Embolism
Do Not Combine
Thromboembolism
Do Not Combine
Thrombophilia
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Estradiol may interact with Pulse Frequency
There are 20 known major drug interactions with Estrace.
Common Estrace Drug Interactions
Drug Name
Risk Level
Description
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Estradiol.
Anagrelide
Major
The metabolism of Anagrelide can be decreased when combined with Estradiol.
Anastrozole
Major
The therapeutic efficacy of Anastrozole can be decreased when used in combination with Estradiol.
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Estradiol.
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Estradiol.
Estrace Toxicity & Overdose RiskThe highest safe dose of estradiol found in rats after 90 days of testing was 0.003mg/kg/day. The lowest toxic dose in women is 21mg/kg/21D. An overdose of estradiol can cause nausea, vomiting, stomach pain, breast tenderness, blood clots in the veins, and vaginal bleeding. If an overdose occurs, it is important to stop taking the medication and get supportive care.
image of a doctor in a lab doing drug, clinical research

Estrace Novel Uses: Which Conditions Have a Clinical Trial Featuring Estrace?

867 active clinical experiments are being conducted to assess the potential of Estrace to mitigate Osteoporosis, Amenorrhea and Genitourinary Atrophy.
Condition
Clinical Trials
Trial Phases
Hysterectomy
3 Actively Recruiting
Phase 3, Not Applicable
estradiol
0 Actively Recruiting
Birth Control
22 Actively Recruiting
Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2
Postmenopause
5 Actively Recruiting
Phase 2, Not Applicable
Metastatic Breast Cancer
1 Actively Recruiting
Phase 1, Phase 2
Osteoporosis, Postmenopausal
0 Actively Recruiting
Therapeutic procedure
0 Actively Recruiting
moderate to severe symptoms
0 Actively Recruiting
Breast Cancer
21 Actively Recruiting
Phase 2, Phase 1, Not Applicable
Balanitis Xerotica Obliterans
0 Actively Recruiting
Amenorrhea
1 Actively Recruiting
Phase 2
Osteoporosis
27 Actively Recruiting
Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2
Prostate Cancer
69 Actively Recruiting
Not Applicable, Phase 3, Phase 2, Phase 1, Early Phase 1
Breast
0 Actively Recruiting
Urogenital atrophy
0 Actively Recruiting
Low Testosterone
6 Actively Recruiting
Phase 4, Phase 2, Phase 1
Vasomotor System
0 Actively Recruiting
Atrophic Vaginitis
1 Actively Recruiting
Not Applicable
Hot flashes
19 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 3
Hormone Replacement Therapy
0 Actively Recruiting

Estrace Reviews: What are patients saying about Estrace?

5Patient Review
1/6/2013
Estrace for Low Estrogen After Operation to Remove Ovaries
I started taking Estrace in 2001 after a hysterectomy, and it's been really effective in combating hot flashes. I'm 60 now but still feel 49. No side effects that I've noticed.
5Patient Review
2/12/2019
Estrace for Low Estrogen After Operation to Remove Ovaries
I've been taking this medication for almost 30 years now with no issues whatsoever. It works great for me, better than the generic brand. I have tried other brands but they caused problems with my vision. Estrace is expensive, but it's worth it to me.
5Patient Review
7/27/2013
Estrace for "Change of Life" Signs
I've been taking Estradiol for over a year now, and I have no complaints. It's helped me a lot and I haven't experienced any negative side effects that I can attribute to the drug.
5Patient Review
7/26/2013
Estrace for "Change of Life" Signs
I cannot believe how well this medicine worked. My OB/GYN recommended it to me and said it would take less than 90 days to see results and they were absolutely right.
5Patient Review
11/5/2011
Estrace for Low Estrogen After Operation to Remove Ovaries
Estrace has been effective for me in managing my hot flashes and other mood swings since my hysterectomy.
5Patient Review
3/21/2014
Estrace for Low Estrogen After Operation to Remove Ovaries
This treatment really helped me. I'm grateful for modern medicine.
5Patient Review
3/4/2013
Estrace for Post-Menopausal Osteoporosis Prevention
This Rx has worked fine for me, but I need to know if this is the lowest dose?
5Patient Review
8/19/2011
Estrace for Low Estrogen After Operation to Remove Ovaries
I've been taking this medication for a decade now, and it's really worked well for me throughout that time. No problems whatsoever.
4.3Patient Review
9/26/2014
Estrace for Vaginal Inflammation due to Loss of Hormone Stimulation
This treatment helped me with my bloating and bladder pressure. It was a bit uncomfortable at first, but it definitely made a difference.
4Patient Review
11/2/2014
Estrace for Vaginal Inflammation due to Loss of Hormone Stimulation
I experienced some intense side effects while taking this medication, including hair loss and weight gain. As soon as I stopped taking the medication, those symptoms went away.
4Patient Review
12/20/2013
Estrace for Post-Menopausal Osteoporosis Prevention
I recently switched from Premarin to Estradiol, as the former was becoming too expensive. So far, I'm pleased with the results of this generic drug; however, only time will tell if it's truly effective for me long-term.
3.7Patient Review
5/19/2012
Estrace for Low Estrogen After Operation to Remove Ovaries
The medication was effective, but after six months of use I found a small lump in my right breast. I don't know if the medication caused it, but it scared me enough to discontinue using it.
3.7Patient Review
10/26/2011
Estrace for Low Estrogen After Operation to Remove Ovaries
I had surgery years ago and was put on Premarin. It worked well for me for many years, but then my doctor switched me to Estrace. While it does alleviate hot flashes and mood swings, the weight gain, headaches, and body aches are becoming too much to bear. I have an appointment with the doctor soon to change medications.
2.7Patient Review
10/11/2013
Estrace for Low Estrogen After Operation to Remove Ovaries
The cream itself works well, but the applicator is very poorly designed and unhygienic.
2Patient Review
8/21/2012
Estrace for Low Estrogen After Operation to Remove Ovaries
I've only been on this medication for two weeks, and I will continue taking it for another month to give it a fair chance. The only side effect I've experienced so far is body aches, which has made it difficult to stick to my workout routine.
1.3Patient Review
4/10/2014
Estrace for "Change of Life" Signs
I took Estrace 0.5 mg tablets for 6 months after switching from vivelle dot patch. I had episodes of racing thoughts, shaking, blood pressure zoomed up to 150/90 (usually 110/70),scared to death what was happening to me. Now I have abdominal pain every day also and I am stopping this scary drug.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about estrace

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the generic name for Estrace?

"Estrace is a female hormone used to treat symptoms of menopause, such as dryness, burning, and itching of the vaginal area, and urgency or irritation with urination."

Answered by AI

How quickly does Estrace work?

"Vaginal atrophy can be treated with topical estrogen including Estrace Vaginal Cream, which can take up to 3 to 4 weeks to reach its full effect."

Answered by AI

What is the drug Estrace used for?

"Use of this medication may also reduce the risk of developing osteoporosis.

This medication is used to help reduce symptoms of menopause in women, such as hot flashes and vaginal dryness. These symptoms are caused by the body making less estrogen, and using this medication may also help to reduce the risk of developing osteoporosis."

Answered by AI

Is Estrace the same as estrogen?

"Estrace contains estrogen, which is produced naturally by the body. Menopause can result in a decreased production of estrogen, which can lead to symptoms such as vaginal dryness, itching, and burning. Estrace can help to reduce or eliminate these symptoms."

Answered by AI

Clinical Trials for Estrace

Image of Altasciences in Mount Royal, Canada.

Elinzanetant for Hot Flashes

18 - 65
Female
Mount Royal, Canada
The aim of this study is to examine the relative bioavailability of elinzanetant when administered in new oral formulations (treatment B and C) after both single and multiple oral doses, compared to its administration in soft gel capsule form (treatment A). Study details include: An ambulatory screening visit within 4 weeks prior to first treatment. Participants will be admitted to the ward on Day -1 of each period. On Day 1, either treatment B or treatment C will be administered fasted in the evening, followed by blood sampling for a 24-hour pharmacokinetic (PK) profile. On Day 2, the multiple dosing starts 3 hours after a standardized dinner in the evening. After the last dosing on Day 7, a complete PK profile for 24 hours will be collected. If there are no medical objections, participants will be discharged from the study ward on Day 9 in the morning for a washout-out period of at least 10 days (240 hours after last dosing, after period 1 and 2) or, in period 3, after the follow-up examination. The total duration of the study will be approximately 10 to 12 weeks for each participant.
Phase 1
Recruiting
AltasciencesBayer
Image of Washington University School of Medicine in St Louis, United States.

Radium-223 for Prostate Cancer

18+
Male
St Louis, MO
Internal radiotherapies (radiolabeled molecules that are systemically administered and localize to sites of disease) provide cancer-ablating doses to diseased cells while sparing adjacent normal tissues. \[223Ra\]RaCl2 (Xofigo) is the first FDA-approved alpha-particle emitting radiopharmaceutical therapy (αRPT), providing a survival benefit for men with bone metastatic castration-resistant prostate cancer. Systemically administered radiotherapies distribute throughout the patient, accumulating to unknown levels at sites of disease and in radiosensitive vital organs. The whole-body distribution means that absorbed doses in the patient extend far beyond a pre-defined treatment field. There is a lack of information about αRPT distribution and localization, and this confounds treatment monitoring, complicates dose and schedule personalization, and impedes drug development. Single-photon emission computed tomography (SPECT) imaging offers a mechanism to quantify uptake; however, αRPT administered activities are significantly lower than those used with diagnostic procedures, which presents a challenge for quantitation with conventional methods. Preliminary research shows that low-count quantitative SPECT (LC-QSPECT) imaging demonstrates reliable quantitation of regional uptake for αRPTs. The purpose of this study is to demonstrate the feasibility, tolerability and performance of LC-QSPECT imaging.
Waitlist Available
Has No Placebo
Washington University School of MedicineAbhinav K Jha, Ph.D.
Image of City of Hope Medical Center in Duarte, United States.

Oral Cryotherapy for Prostate Cancer

18+
Male
Duarte, CA
This clinical trial studies whether cooling the mouth with popsicles (oral cryotherapy) decreases taste changes in prostate cancer patients receiving taxane chemotherapy. Patients receiving chemotherapy can experience a variety of side effects. Changes in the taste of food is a frequent complaint of patients receiving chemotherapy and is underreported as patients may think that it is unavoidable and not manageable. Taxane-based chemotherapy is thought to be associated with the most taste changes of any chemotherapy. Taste buds contain a specific type of cell, called gustatory cells, that are located on the surface of the tongue, the soft palate (back, muscular part of the roof of the mouth), and the upper part of the esophagus. These cells consist of five basic tastes: salty, sweet, sour, bitter, and umami (or savory). Oral cryotherapy involves cooling the mouth with ice chips, popsicles, or other cold drinks for several minutes before, during, and after chemotherapy causing the tiny blood vessels in the protective linings inside the mouth to narrow. It is thought that this narrowing will reduce blood flow to the cooled areas, thereby decreasing the amount of chemotherapy that is delivered to the fragile protective linings inside the mouth that causes the taste changes. This may be an effective way to decrease taste changes in prostate cancer patients receiving taxane chemotherapy.
Waitlist Available
Has No Placebo
City of Hope Medical CenterJeannine M Brant
Image of Erevna Innovations Inc. in Montreal, Canada.

Sculptra + Restylane for Post-Menopausal Skin Concerns

40 - 65
Female
Montreal, Canada
The post-menopausal state is marked by a sharp decline in estrogen, leading to significant structural and functional changes in the skin, including collagen loss, dryness, thinning, and reduced elasticity. To address these concerns, aesthetic injectables products such as Sculptra® Aesthetic (poly-L-lactic-acid \[PLLA- SCA\]) and Restylane Skinboosters®\[HASBV\] (small-particle hyaluronic acid - SP-HA) can be used. PLLA-SCA stimulates collagen production via cellular activation (biostimulator), gradually improving dermal structure. HASBV enhances hydration, elasticity, and skin texture when injected under the skin. Considering that hydration and laxity represent the primary aesthetic concerns in this patient population. Targeted treatment with SP-HA (HASBV) to improve hydration and PLLA-SCA to address laxity have been shown to produce significant clinical outcomes by directly addressing these key dermal deficiencies. This approach forms the basis of the current study.
Phase 4
Recruiting
Erevna Innovations Inc.Andreas Nikolis, MD, PhD
Have you considered Estrace clinical trials? We made a collection of clinical trials featuring Estrace, we think they might fit your search criteria.Go to Trials
Image of UCLA / Jonsson Comprehensive Cancer Center in Los Angeles, United States.

Flotufolastat F 18 PET/CT for Prostate Cancer

18 - 90
Male
Los Angeles, CA
This phase II trial evaluates how well flotufolastat F 18 positron emission tomography (PET)/computed tomography (CT) imaging works to detect cancer that remains (residual) or that has come back (recurrent) after the completion of focal therapy for prostate cancer. Flotufolastat F 18 is a radioactive tracer that binds to prostate specific membrane antigen (PSMA), a protein over-expressed on prostate tumor cells. This allows for visualization of PSMA-expressing cells upon imaging. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of, in the case of this research, flotufolastat F 18. Because prostate cancer takes up flotufolastat F 18, it can be seen with PET. CT utilizes x-rays that track the body from the outside. CT images provide an exact outline of the organs and potential inflammatory tissue where it occurs in the body. The PET/CT scanner combines the PET and the CT scanners into a single device. This device combines the anatomic (body structure) information provided by the CT scan with the metabolic information obtained from the PET scan. Metabolic information means how much of the injected tracer is taken up by inflammatory tissue. Flotufolastat F 18 PET/CT imaging may be an effective and less invasive way to detect residual or recurrent disease in prostate cancer patients, compared to other methods.
Phase 2
Recruiting
UCLA / Jonsson Comprehensive Cancer CenterWayne BrisbaneBlue Earth Diagnostics
Image of UCLA / Jonsson Comprehensive Cancer Center in Los Angeles, United States.

PSMA Imaging for Prostate Cancer

18 - 90
Male
Los Angeles, CA
This early phase I trial evaluates whether a new imaging technique using flotufolastat F 18 (a type of prostate specific membrane antigen \[PSMA\] imaging agent) with positron emission tomography (PET)/computed tomography (CT) can be used to guide targeted prostate biopsies in men with prostate cancer. Flotufolastat F 18 is a radioactive imaging agent that binds to prostate tumor cells that express PSMA. This allows for visualization of PSMA-expressing tumor cells on imaging scans such as PET/CT. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, flotufolastat F 18. Because prostate cancer takes up flotufolastat F 18, it can be seen with PET. CT utilizes X-rays that track the body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in the body. The PET/CT scanner combines the PET and the CT scanners into a single device. A targeted prostate biopsy refers to using advanced imaging for guidance when taking samples (biopsies) of the prostate. This method can fuse (combine) PET/CT images with real-time ultrasound during a prostate biopsy. PSMA PET/CT scans have the potential for guiding prostate biopsies. Using image fusion technology, they can increase detection of prostate cancer by providing anatomical information and guidance during a prostate biopsy. Improved detection of prostate cancer using PSMA PET/CT guidance may better inform men and their clinicians about prostate cancer risk and management. This study attempts to determine how often prostate cancer is found when using PSMA PET/CT scan images during a biopsy versus the conventional magnetic resonance imaging-guidance.
Phase < 1
Recruiting
UCLA / Jonsson Comprehensive Cancer CenterWayne BrisbaneBlue Earth Diagnostics
Image of USC / Norris Comprehensive Cancer Center in Los Angeles, United States.

MRI-Based Machine Learning for Prostate Cancer

18+
Male
Los Angeles, CA
This clinical trial studies how well a magnetic resonance imaging (MRI)-based machine learning approach (i.e., artificial intelligence \[AI\]) works as compared to radiologist MRI readings in detecting prostate cancer. One of the current methods used to help diagnose possible prostate cancer is performing a prostate MRI. An MRI uses a magnetic field to take pictures of the body. The MRI images are examined by a radiologist. If a suspicious area is seen in the MRI, the radiologist assigns it a PIRADS score. This stands for Prostate Imaging Reporting and Data System. The PIRADS score is used to report how likely it is that a suspicious area in the prostate is cancer. The AI system has been developed also to be able to analyze prostate MRI images and detect suspicious areas in the prostate that may be cancer. The AI system's ability to diagnose aggressive prostate cancer may be similar to detection performed by experienced radiologists using the standard PIRADS system of analyzing prostate MRI.
Recruiting
Has No Placebo
USC / Norris Comprehensive Cancer CenterAndre Luis Abreu, MD
Have you considered Estrace clinical trials? We made a collection of clinical trials featuring Estrace, we think they might fit your search criteria.Go to Trials
Image of Mayo Clinic in Florida in Jacksonville, United States.

Virtual Reality Assistant for Prostate Cancer

Any Age
Male
Jacksonville, FL
This clinical trial tests how well a point of prostate cancer diagnosis (PPCD) virtual reality assistant (ViRA) intervention works in supporting Black men with newly diagnosed prostate cancer. Cancer is the second leading cause of death for African American/Black men, with prostate cancer leading in estimated new cancer cases and second in estimated new cancer deaths. Over 40,000 African American/Black men are diagnosed with prostate cancer annually, with 1 in 6 lifetime probability of developing prostate cancer compared to 1 in 8 probability in White men. The PPCD ViRA provides psycho-oncology support, social determinants of health navigation and emotional support for ethnically diverse African American/Black men newly diagnosed with prostate cancer using artificial intelligence and augmented reality. Using PPCD ViRA may close the prostate cancer care gap for African American/Black men across the cancer continuum and provide emotional, educational, and resource needs of this population when they are visiting a doctor about their prostate health or prostate cancer.
Waitlist Available
Has No Placebo
Mayo Clinic in FloridaFolakemi T. Odedina, PhD
Image of UCLA / Jonsson Comprehensive Cancer Center in Los Angeles, United States.

Imaging Tracer 68Ga-FAPi-46 for Cancer

18+
All Sexes
Los Angeles, CA
This phase I trial is evaluating a new imaging tracer (68Ga-FAPi-46) with positron emission tomography (PET)/computed tomography (CT) to determine where and to which degree the tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues (the biodistribution) in patients with solid tumors or hematologic (blood) cancers. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 68Ga-FAPi-46. Because some cancers take up 68Ga-FAPi-46, it can be seen with PET. CT utilizes x-rays that traverse the body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in a patient's body. Combining a PET scan with a CT scan can help make the image easier to interpret. PET/CT scans are hybrid scanners that combine both modalities into a single scan during the same examination.
Phase 1
Recruiting
UCLA / Jonsson Comprehensive Cancer CenterJeremie Calais
Have you considered Estrace clinical trials? We made a collection of clinical trials featuring Estrace, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security